855 North Wolfe Street
Suite 601
Baltimore, MD 21205
United States
856 848 8698
https://www.mymd.com
Settore/i:
Settore:
Impiegati a tempo pieno: 6
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Christopher C. Chapman Jr., M.D. | President, Chief Medical Officer & Director | 665,76k | N/D | 1953 |
Mr. Ian Rhodes CPA | Interim Chief Financial Officer | 162k | N/D | 1973 |
Dr. Jenna Brager M.S., Ph.D., R.N. | Executive Vice President of Drug Development | N/D | N/D | N/D |
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
L'ISS Governance QualityScore di MyMD Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.